TY - JOUR
T1 - Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel
AU - Wang, Feihu
AU - Su, Hao
AU - Xu, Dongqing
AU - Dai, Wenbing
AU - Zhang, Weijie
AU - Wang, Zongyuan
AU - Anderson, Caleb F.
AU - Zheng, Mengzhen
AU - Oh, Richard
AU - Wan, Fengyi
AU - Cui, Honggang
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Tumours with an immunosuppressive microenvironment respond poorly to therapy. Activation of the stimulator of interferon genes (STING) pathway can enhance intratumoural immune activation, but STING agonists are associated with high toxicity and degrade prematurely, which limits their effectiveness. Here, we show that the extended intratumoural release of the STING agonist cyclic di-AMP transforms the tumour microenvironment from immunosuppressive to immunostimulatory, increasing the efficacy of antitumour therapies. The STING agonist was electrostatically complexed with nanotubes comprising a peptide–drug conjugate (a peptide that binds to the protein neuropilin-1, which is highly expressed in tumours, and the chemotherapeutic agent camptothecin) that self-assemble in situ into a supramolecular hydrogel. In multiple mouse models of murine tumours, a single low dose of the STING agonist led to tumour regression and increased animal survival, and to long-term immunological memory and systemic immune surveillance, which protected the mice against tumour recurrence and the formation of metastases. Locally delivered STING agonists could help to reduce tumour immunosuppression and enhance the efficacy of a wide range of cancer therapies.
AB - Tumours with an immunosuppressive microenvironment respond poorly to therapy. Activation of the stimulator of interferon genes (STING) pathway can enhance intratumoural immune activation, but STING agonists are associated with high toxicity and degrade prematurely, which limits their effectiveness. Here, we show that the extended intratumoural release of the STING agonist cyclic di-AMP transforms the tumour microenvironment from immunosuppressive to immunostimulatory, increasing the efficacy of antitumour therapies. The STING agonist was electrostatically complexed with nanotubes comprising a peptide–drug conjugate (a peptide that binds to the protein neuropilin-1, which is highly expressed in tumours, and the chemotherapeutic agent camptothecin) that self-assemble in situ into a supramolecular hydrogel. In multiple mouse models of murine tumours, a single low dose of the STING agonist led to tumour regression and increased animal survival, and to long-term immunological memory and systemic immune surveillance, which protected the mice against tumour recurrence and the formation of metastases. Locally delivered STING agonists could help to reduce tumour immunosuppression and enhance the efficacy of a wide range of cancer therapies.
UR - http://www.scopus.com/inward/record.url?scp=85089190009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089190009&partnerID=8YFLogxK
U2 - 10.1038/s41551-020-0597-7
DO - 10.1038/s41551-020-0597-7
M3 - Article
C2 - 32778697
AN - SCOPUS:85089190009
SN - 2157-846X
VL - 4
SP - 1090
EP - 1101
JO - Nature biomedical engineering
JF - Nature biomedical engineering
IS - 11
ER -